Valuation: Roche Holding AG

Market Cap 317B 377B 344B 288B 541B 34,952B 568B 3,855B 1,532B 19,091B 1,416B 1,386B 59,914B P/E 2026 *
21.4x
P/E 2027 * 19.2x
Enterprise Value 328B 391B 357B 299B 561B 36,245B 589B 3,998B 1,589B 19,797B 1,469B 1,438B 62,131B EV / Sales 2026 *
5.17x
EV / Sales 2027 * 4.86x
Free-Float
88.78%
Yield 2026 *
2.53%
Yield 2027 * 2.59%
1 day-0.59%
1 week-2.28%
Current month-2.09%
1 month+1.36%
3 months+6.06%
6 months+20.25%
Current year+20.11%
1 week 401.8
Extreme 401.8
417
1 month 387.6
Extreme 387.6
417.8
Current year 301.2
Extreme 301.2
417.8
1 year 301.2
Extreme 301.2
417.8
3 years 229.4
Extreme 229.4
417.8
5 years 229.4
Extreme 229.4
439.2
10 years 209.4
Extreme 209.4
439.2
Manager TitleAgeSince
Chief Executive Officer 51 15/03/2023
Director of Finance/CFO 59 06/06/2011
Chief Operating Officer - 01/10/2025
Director TitleAgeSince
Director/Board Member 68 01/01/1996
Chairman 59 15/03/2023
Director/Board Member 73 03/03/2015
Change 5-day change 1-year change 3-year change Capi.($)
-0.59%-2.28% - - 377B
-0.30%-6.68%+27.12%+127.32% 1,200B
+1.25%-5.35%+32.65%+78.98% 651B
+0.94%-2.99%+21.13%+106.30% 506B
-0.60%-1.95%+25.73%+67.00% 377B
+0.69%-9.50%+36.78%+30.83% 330B
+0.41%-4.70%+24.18%+50.18% 288B
+0.81%-4.08%-2.95%+31.59% 272B
-0.15%-6.45%+29.06%+65.76% 236B
-0.06%-0.98%+31.42%+122.83% 206B
Average +0.24%-4.76%+25.01%+75.64% 452B
Weighted average by Cap. +0.22%-5.19%+26.02%+87.88%

Financials

2026 *2027 *
Net sales 63.51B 75.67B 68.92B 57.77B 108B 7,007B 114B 773B 307B 3,827B 284B 278B 12,012B 66.29B 78.99B 71.95B 60.3B 113B 7,315B 119B 807B 321B 3,995B 296B 290B 12,539B
Net income 14.81B 17.64B 16.07B 13.47B 25.27B 1,634B 26.56B 180B 71.62B 892B 66.19B 64.8B 2,800B 16.49B 19.65B 17.9B 15B 28.14B 1,820B 29.58B 201B 79.78B 994B 73.73B 72.18B 3,119B
Net Debt 11.72B 13.97B 12.72B 10.66B 20.01B 1,293B 21.03B 143B 56.71B 706B 52.41B 51.3B 2,217B 5.25B 6.26B 5.7B 4.78B 8.96B 579B 9.42B 63.9B 25.4B 316B 23.47B 22.98B 993B
Projected Income Statement - Annual - Roche Holding AG
Logo Roche Holding AG
Roche Holding AG (Roche) is a research-based healthcare company. The Company's operating businesses are organized into two divisions: Pharmaceuticals and Diagnostics. The Pharmaceuticals Division consists of two business segments: Roche Pharmaceuticals and Chugai. The Diagnostics Division consists of four business areas: Diabetes Care, Molecular Diagnostics, Professional Diagnostics and Tissue Diagnostics. The Company develops medicines for various disease areas, including oncology, immunology, infectious diseases, ophthalmology and neuroscience. Its pharmaceutical products include Anaprox, Avastin, Bactrim, Bondronat, CellCept, Cotellic, Dilatrend, Dormicum, Invirase, Kadcyla, Kytril (Kevatril), Lariam, MabThera, Madopar, Neupogen, Pegasys, Perjeta, Pulmozyme, Rocaltrol, Rocephin and Roferon-A. The Company offers products for researchers, including cell analysis, gene expression, genome sequencing and nucleic acid purification.
Employees
103,249
Date Price Change Volume
20/11/26 CHF 402.60 -0.59% 33,250
19/11/26 CHF 405.00 -0.64% 29,233
18/11/26 CHF 407.60 -0.83% 25,136
17/11/26 CHF 411.00 -0.77% 27,206
16/11/26 CHF 414.20 +0.53% 34,103
Trader
Investor
Global
Quality
ESG MSCI
-
MarketScreener Ratings - Roche Holding AG
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
22
Last Close Price
396.80CHF
Average target price
397.79CHF
Spread / Average Target
+0.25%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - Roche Holding AG